|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.870 USD | +1.77% |
|
-3.69% | +4.36% |
Company Valuation: Perspective Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.03 | 35.12 | 112.8 | 215.6 | 204.4 | 327.3 | - | - |
| Change | - | -36.19% | 221.19% | 91.16% | -5.18% | 60.11% | - | - |
| Enterprise Value (EV) 1 | 55.03 | 35.12 | 112.8 | -8.207 | 61.26 | 140.2 | 15.01 | 140.7 |
| Change | - | -36.19% | 221.19% | -107.28% | 846.48% | 128.84% | -89.29% | 837.19% |
| P/E | -12.9x | -4.94x | -2.36x | -2.59x | -1.96x | -2.6x | -2.53x | -2.69x |
| PBR | - | - | - | 0.78x | 0.99x | 1.27x | 1.09x | 1.53x |
| PEG | - | -0.1x | -0x | 0.1x | -0.1x | 0.1x | -0.93x | 0.45x |
| Capitalization / Revenue | 5.47x | 9.89x | 78.7x | 148x | 231x | 773x | 671x | 24.3x |
| EV / Revenue | 5.47x | 9.89x | 78.7x | -5.64x | 69.3x | 331x | 30.8x | 10.4x |
| EV / EBITDA | -19.1x | - | - | 0.13x | -0.56x | -1.11x | -0.1x | -0.92x |
| EV / EBIT | -16x | - | -2.75x | 0.12x | -0.54x | -1.12x | -0.1x | -0.97x |
| EV / FCF | - | - | -2.97x | 0.11x | -0.64x | -1.34x | -0.11x | -0.94x |
| FCF Yield | - | - | -33.7% | 886% | -155% | -74.4% | -924% | -107% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.5 | -1.7 | -1.23 | -1.4 | -1.104 | -1.134 | -1.066 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.05 | 3.552 | 1.434 | 1.454 | 0.884 | 0.4232 | 0.4875 | 13.49 |
| EBITDA 1 | -2.874 | - | - | -64.49 | -110.3 | -126.9 | -144.2 | -153 |
| EBIT 1 | -3.446 | - | -40.94 | -66.8 | -113.6 | -125.4 | -144.8 | -144.5 |
| Net income 1 | -3.39 | - | -46.51 | -79.28 | -103.1 | -120.1 | -138.1 | -137 |
| Net Debt 1 | - | - | - | -223.8 | -143.2 | -187.1 | -312.3 | -186.7 |
| Reference price 2 | 3.878 | 2.471 | 4.020 | 3.190 | 2.750 | 2.870 | 2.870 | 2.870 |
| Nbr of stocks (in thousands) | 14,192 | 14,211 | 28,057 | 67,588 | 74,338 | 114,046 | - | - |
| Announcement Date | 9/21/21 | 5/1/23 | 3/28/24 | 3/26/25 | 3/16/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.56x | 317.81x | -1.06x | -.--% | 322M | |
| 32.79x | 5.87x | 17.42x | 1% | 47.74B | |
| -23.47x | 352.2x | -21.51x | -.--% | 39.98B | |
| 48.32x | 4.93x | 31.87x | -.--% | 36.23B | |
| 25.95x | 2.85x | 12.32x | -.--% | 35.59B | |
| 27.91x | 7.98x | 19.84x | 0.43% | 27.91B | |
| 33.62x | 5.49x | 25.05x | -.--% | 16.45B | |
| 22.1x | 1.97x | 8.54x | 1.19% | 13.21B | |
| 23.86x | 1.9x | 11.51x | -.--% | 12.93B | |
| Average | 20.95x | 77.89x | 11.55x | 0.29% | 25.6B | |
| Weighted average by Cap. | 22.71x | 65.58x | 12.12x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CATX Stock
- Valuation Perspective Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
